For the quarter ending 2026-03-31, VERA had -$240,374K decrease in cash & cash equivalents over the period. -$106,523K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -121,032 | -91,097 | -80,293 | -128,225 |
| Depreciation and amortization | 140 | 135 | 129 | 204 |
| Payment of vt-109 license fee | - | 0 | 0 | 800 |
| Accretion of discount and amortization of premium on debt securities, net | - | - | -1,451 | -4,421 |
| Accretion of discount and amortization of premium on purchase of debt securities | -843 | -6,981 | - | - |
| Accretion of loan exit fee and amortization of loan costs, net | - | - | 843 | 377 |
| Accretion of loan exit fee and amortization of loan costs | 639 | 1,857 | - | - |
| Reduction in the carrying amount of operating lease right-of-use assets | 116 | 113 | 435 | 901 |
| Stock-based compensation | 13,208 | 10,965 | 9,745 | 17,216 |
| Upfront and milestone obligations under license agreements | 15,000 | - | - | - |
| Prepaid expense and other current assets | 5,143 | 372 | -606 | 4,162 |
| Other assets | 0 | -1 | 108 | -158 |
| Accounts payable | -7,966 | 3,625 | 4,793 | 5,492 |
| Accrued and other liabilities | -437 | 7,208 | 3,915 | 3,319 |
| Operating lease liabilities | -182 | -100 | -520 | -863 |
| Net cash used in operating activities | -106,500 | -69,994 | -61,906 | -109,204 |
| Proceeds from maturities of marketable securities | - | - | 400,897 | - |
| Proceeds from sale of marketable securities | - | 0 | 0 | 0 |
| Upfront and milestone payments under license agreements | 15,000 | - | - | - |
| Payment of vt-109 license fee | - | 0 | 0 | 800 |
| Purchase of internal use software license | 150 | - | - | - |
| Purchase of property and equipment | 23 | 102 | 133 | 395 |
| Purchase of marketable securities | 210,561 | 24,499 | 98,696 | 187,251 |
| Proceeds from maturities of marketable securities | 87,918 | 273,855 | - | 232,307 |
| Net cash (used in) provided by investing activities | -137,816 | 80,664 | 69,761 | 43,861 |
| Proceeds from short swing settlement | - | 500 | 0 | 0 |
| Proceeds from borrowings, net of costs | - | 0 | - | - |
| Repurchase of common stock | - | 0 | 0 | - |
| Proceeds from issuance of common stock in follow-on offerings | - | 300,000 | 0 | 0 |
| Payment of issuance costs and underwriting fees related to follow-on offerings | - | 18,405 | 0 | 0 |
| Payment of deferred issuance costs related to unfunded loan commitments | - | 0 | 0 | 3,517 |
| Proceeds from refinancing under loan and security agreement, net | - | 0 | 0 | 23,338 |
| Proceeds from exercise of stock options and employee stock purchase plan | 3,942 | 4,187 | 797 | 1,997 |
| Net cash provided by financing activities | 3,942 | 286,282 | 797 | 21,818 |
| Net decrease in cash and cash equivalents | -240,374 | 296,952 | 8,652 | -43,525 |
| Cash and cash equivalents, beginning of period | 354,725 | 57,773 | 92,646 | - |
| Cash and cash equivalents, end of period | 114,351 | 354,725 | 57,773 | - |
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)